#### TABLE OF CONTENTS

		Page
ACKNOWLEDGEMENT		iii
	ABSTRACT (ENGLISH)	
ABSTRACT (		vi
LIST OF TAI		xi
LIST OF FIG	URES	xiv
ABBREVIAT		XV
CHAPTER 1	INTRODUCTION	1
CHAPTER 2	LITERATURE REVIEWS	8
	1. Drug management system	8
	1.1 Concepts of Drug Management System	8
	1.2 Concepts of Thailand's National Drug Policy 2011	9
	1.3 Concepts of Thailand's National List of Essential	
	Drugs 2008	11
	1.4 The policy of National Health Security Office 2010	13
	1.5 The Guideline of Drug Management System under	
	MOPH 1999	14
	2. DSM situation in Thailand	15
	2.1 National level	16
	2.2 Provincial level	21
	2.3 Hospital level	22
	3. Quality indicators (QIs) for monitoring and evaluation of	
	Drug System Management (DSM) performance at the	
	community hospitals under MOPH	28
	4. Quality indicators	45
	5. Delphi technique	45
	6. Literature reviews of DSM	53

CHAPTER 3	METHODOLOGY	58
	1. Research design	58
	2. Scope of the research	58
	3. Research framework	59
	4. Research methodology	59
	4.1 Part 1: Gathering of QIs related to 10 key issues of	
	DSM	60
	4.2 Part 2: Selecting the potential QIs	62
	4.3 Part 3: Test of a set of potential QIs of DSM	65
CHAPTER 4	RESULTS AND DISCUSSION	68
	1. Part 1: Gathering of QIs related to 10 key issues of	
	DSM	68
	2. Part 2: Selecting the potential QIs	98
	3. Part 3: Test of a set of potential QIs of DSM	145
CHAPTER 5	CONCLUSIONS	164
REFERENCE	CS CS	169
APPENDICE	s	180
	Appendix A Quality Indicators of DSM	181
	Appendix B List of DSM specialists	288
	Appendix C List of community hospitals	289
CURRICULU	UM VITAE	290

## LIST OF TABLES

Table	Page
2.1 The guideline of measurement of efficiency improvement on DSM 1999	23
2.2 Guideline driven indicators developed using an iterated consensus rating	52
Procedure	
3.1 List of searched terms for QIs of DSM	60
3.2 Number of community hospitals classified by number of hospital beds	
in four provinces under MOPH, region 15	66
4.1 The purposes of 10 key issues related to DSM	69
4.2 Key issues and datasources of QIs	71
4.3 Number and percentage of QIs classified following 10 key issues of DSM	72
4.4 201 QIs related to the 10 key issues of DSM	73
4.5 Number of QIs following 10 key issues of DSM and 4 components of	
Logic model	92
4.6 Importance and validity 57 QIs of resource component	100
4.7 Importance and validity of 59 QIs of activity component	102
4.8 Importance and validity 80 QIs of output component	105
4.9 Importance and validity 5 QIs of outcome component	107
4.10 Number of QIs classified in 4 criterions	108
4.11 Number of excluded QIs and selected QIs following 10 key issues	
of DSM and 4 components of Logic model	109
4.12 84 QIs were selected in the first Delphi round	111
4.13 Median and inter-quartile range of appropriateness, congruence,	
and feasibility of 23 QIs in resource component (the first Delphi round)	114
4.14 Median and inter-quartile range of appropriateness, congruence,	
and feasibility of 32 QIs in activity component (the first Delphi round)	116
4.15 Median and inter-quartile range of appropriateness, congruence,	
and feasibility of 26 OIs in output component (the first Delphi round)	110

4.16	Median and inter-quartile range of appropriateness, congruence,	
	and feasibility of 3 QIs in outcome component (the first Delphi round)	120
4.17	Median and inter-quartile range of appropriateness, congruence,	
	and feasibility of 23 QIs in resource component (the second Delphi	
	round)	122
4.18	Median and inter-quartile range of appropriateness, congruence,	
	and feasibility of 32 QIs in activity component (the second Delphi	
	round)	125
4.19	Median and inter-quartile range of appropriateness, congruence,	
	and feasibility of 26 QIs in output component (the second Delphi	
	round)	127
4.20	Median and inter-quartile range of appropriateness, congruence,	
	and feasibility of 3 QIs in outcome component (the second Delphi	
	round)	128
4.21	The opinion of twenty experts for consensus or dissensus of 84 QIs of	
	the two rounds of Delphi technique	129
4.22	Inter-rater reliability of agreement by twenty experts	132
4.23	Code of QIs and number of QIs following 10 key issues of DSM	132
4.24	Number and percentage of the results of 11 QIs in resource component	148
4.25	Number and percentage of the results of 16 QIs in activity component	152
4.26	Statistic values of 19 QIs in output component	156
4.27	Statistic values of QI in outcome component	156
4.28	Reliability value of QIs in resource component (11 QIs), activity	
	components (16 QIs), and total of QIs from resource and activity	
	components (27 QIs)	158
4.29	Statistic value of the score of drug safety standard from 30 community	
	hospitals	158
4.30	Pearson correlation coefficient (r) for the relation of each QI in resource	
	component with the assessment score of the drug safety standard	159
4.31	Pearson correlation coefficient (r) for the relation of each QI in activity	
	component with the assessment score of the drug safety standard	160

4.32 Spearman's correlation coefficient (r<sub>s</sub>) for the relation of each QI inoutput component with the assessment score of the drug safety standard161

162

4.33 Spearman's correlation coefficient (r<sub>s</sub>) for the relation of the QI in outcome component with the assessment score of the drug safety standard

AT UNIVERSITA

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่ Copyright<sup>©</sup> by Chiang Mai University All rights reserved

#### LIST OF FIGURES

Figure	Page
2.1 Drug Management Cycle	9
3.1 Research framework of DSM at community hospitals	59
3.2 A systematic review process in part 1	61

# ลิขสิทธิ์มหาวิทยาลัยเชียงใหม Copyright<sup>©</sup> by Chiang Mai University All rights reserved

### ABBREVIATION AND SYMBOLS

ADE = Adverse Drug Event

ADR = Adverse Drug Reaction

ADS = Automated Dispensing System

ASU = Antibiotic Smart Use

CIHI = Canadian Institute for Health Information

COA = Certificate of Analysis

CSMBS = Civil Service Medical Benefit Scheme

DMSIC = Drugs and Medical Supplies Information Center

DSM = Drug System Management

DTC = Drug and Therapeutics Committee

DUE = Drug Utilization Evaluation

DUR = Drug Utilization Review

ED = Essential Drugs

EU-MED-STAT = The EU-MED-STAT Group

FDA = Food and Drug Administration

GPO = Government Pharmaceutical Organization

HA = Healthcare Accreditation

HAD = High Alert Drug

HCFA = Health Care Financing Administration

HCS = Health Care System

INRUD = International Network for Rational Use of Drugs

JCAHO = Joint Commission on Accreditation of Health Care

Organization

MSH = Management Sciences for Health

MOPH = Ministry of Public Health

NCQA = National Committee for Quality Assurance

NDP = National Drug Policy

NED = Non Essential Drug

NHS = National Health Service

NHSO = National Health Security Office

NLED = National List of Essential Drug

NPS = National Prescribing Service Limited

PAHO = Pan American Health Organization

PCU = Primary Care Unit

PDUSRS = Prescription Drug Utilization Standards and Reporting

System

PING = Prescribing Indicators National Group

PSyRIC = Pharmaceutical System Research and Intelligence Center

PTC = Pharmacy and Therapeutic Committee

QI = Quality Indicator

RUD = Rational Use of Drug

SMP = Safety Monitoring Program

SSS = Social Security Scheme

STG = Standard Treatment Guideline

TAG = Therapeutic Assessment Group

TGA = Therapeutic Goods Administration

UCS = Universal Coverage Scheme

UC = Universal Coverage

UK = United Kingdom

UN = United Nations

USA = United States of America

WHO = World Health Organization